Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …

Introduction This study evaluated whether tumor expression of programmed death ligand 1
(PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase …

Objectives The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with …

Introduction Epidermal growth factor receptor (EGFR) mutation status was reported to be
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular …

Background Although EGFR mutant tumors exhibit low response rates to immune
checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; …

Introduction Several studies have demonstrated that non-small cell lung cancer patients
(NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical …

Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …

Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …

Background Insertions in exon 20 (Ex20ins) of epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and …

Background The ATLANTIC trial reported that higher PD-L1 expression in tumors was
involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung …